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RAPPORT DE SYNTHESE 
Corrélation génotypique-phénotypique de la dégénérescence 
maculaire liée à l'âge: influence du polymorphisme du gène 
complement factor H 
La dégénérescence maculaire liée à l'âge (DMLA) est une maladie très fréquente qui 
représente la cause principale de cécité légale chez les sujets de plus de 50 ans en Occident. 
Bien que l'étiologie exacte de cette affection ne soit pas complètement connue, des facteurs 
environnementaux et génétiques influencent sa survenue et son évolution. A ce sujet, de 
récentes recherches ont notamment montré une association marquée à une variante du gène 
CFH, Y 402H. Nous ignorons toutefois si le polymorphisme Y 402H est associé à un 
phénotype particulier de la maladie. 
Cette étude a pour but d'établir si cette variante du gène CFH est associée à certaines 
caractéristiques phénotypiques précoces. 
L'étude porte sur quatre cent vingt patients atteints de DMLA qui ont été phénotypés sur la 
base de photographie du fond d'œil (International Classification and Grading system for age-
related macular degeneration) et génotypés à partir d'ADN leucocytaire à la recherche de la 
variante Y 402H du gène CFH. Ces données ont ensuite fait l'objet d'une analyse statistique de 
l'association génotype-phénotype (le génotype de 50 sujets-contrôle a été utilisé pour 
confirmer l'association du polymorphisme avec la DMLA). 
Les résultats obtenus, corrigés pour l'âge et le sexe, montrent un odds ratio (OR) de 
développer une DMLA de 2.95 en présence d'au moins un allèle à risque Cet de 9.05 pour les 
homozygotes CC. Par contre, aucune influence n'est observée sur les stades de la maladie 
(précoce-tardif). Une association significative entre le génotype CC et la présence de druses 
périphériques (p=0.028), ainsi que la localisation centrale des druses (p=0,049) a été mise en 
évidence. Aucune autre tendance n'a été dégagée concernant les critères restants (taille, 
smface totale recouverte, localisation nasale des druses) ou les changements pigmentaires. 
Cette étude a permis de confirmer l'association entre la variante Y 402H et la DMLA dans la 
population suisse et de conclure que la variante Y 402H du gène CFH présente une association 
gêna-phénotypique pour certaines caractéristiques des druses. Il est probable que d'autres 
facteurs génétiques encore influencent le phénotype de la DMLA. 
De nouvelles recherches seront nécessaires pour préciser l'influence de ces autres facteurs 
génétiques ou environnementaux, en vue d'une meilleure compréhension de la pathogenèse de 
cette affection, et pour développer des mesures thérapeutiques et prophylactiques adaptées . 
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Genotype-phenotype correlation of age-related 
macular degeneration: influence of complement 
factor H polymorphism 
1 Droz,1 1 Mantel,1 A Ambresin, 1 M Faouzi,2 D F Schorderet,3 F L Munier1 
ABSTRACT 
Bacl<ground/aims: Complement factor H (CFH) Y402H 
polymorphism shows a strong association with age-
related macular degeneration (AMD). Although the 
phenotypic concordance of AMD has been shown in 
sibling/twin studies, little is known about the genotype-
phenotype association. ln this study, we investigated 
whether CFH Y 402H is associated with early phenotypic 
features. 
Methods: Statistical analysis was performed on 420 
patients with AMD with complete clinical and genetic 
data (graded colour fundus photographs, according to the 
International Classification and Grading System for AMD 
and successful testing for CFH Y 402H). 
Results: ln this Swiss population, an OR of 2.95 was 
confirmed for AMD in the presence of at least one risk C 
allele and OR of 9.05 for the CC homozygotes, corrected 
for age and sex. No difference was found between the 
AMD stages. Patients homozygous for the risk allele 
showed significant association with peripheral drusen 
(p = 0.028) and for central drusen location (p = 0.049). 
No trend was found for other drusen criteria (size, total 
surface, location nasal to dise) and for pigmentary 
changes. 
Conclusions: The CFH Y402H polymorphism showed a 
genotype-phenotype association for some drusen fea-
tures. Additional genetic factors are likely to influence 
drusen phenotype. 
Age-related macular degeneration (AMD) is the 
leading cause of severe visual impairment in the 
Western world among people over 50 years of age 
due to vision-threatening late complications such 
as geographic atrophy (GA) and choroidal neo-
vascularisation (CNV).1-5 
Numerous genetic6 7 as well as environmental 
factors 8 9 have been shown to be involved in the 
pathogenesis of AMD. Family and twin studies, as 
well as population-based genetic epidemiological 
studies, have convincingly demonstrated the 
importance of genetics in AMD,10-.17 with a herit-
ability estimated to be between 46 and 71 %. 17 
Phenotypically, impressive concordance of clinical 
features of AMD (in both its early and late forms) 
was shown in monozygotic twin studies of 
AMD, 17-19 and to a lesser degree in sibling studies. 15 
Recently, a number of polymorphisms have been 
identified for their risk association with AMD.6 7 
The polymorphism that was first detected is 
located in the gene for complement factor H 
(CFH), an important regulator of the complement 
system. CFH polymorphism Y402H (rs1061170) is 
one of the two most significant AMD genetic risk 
factors described to date,20-.29 the second being 
LOC387715 (rs10490924, Ala69Ser).24 29-32 
Investigation of the phenotypic association was 
concentrated on the late forms of AMD, namely GA 
and CNV with inconsistent results.20 22 23 27 28 30 s1 33-3s 
However, little is known about the association with 
early features of AMD. 
CFH is also implicated in membranoproliferative 
glomerulonephritis (MPGN) type II, a renal dis-
order associated with a particular type of drusen, 
referred to as "cuticular". In addition, CFH 
polymorphism is significantly more common in 
patients with cuticular drusen, independent of 
MPGN II. 39 Complement factors, including factor 
H, are known to accumulate within drusen. 22 40 41 
The purpose of the present study was to 
determine whether or not we could find a 
genotype-phenotype association in early AMD 
for the CHF Y402H polymorphism. Such knowl-
edge would increase our understanding of the 
disease, and should ultimately help to improve its 
management. 
METHODS 
Study population: AMD cases 
All study participants were recruited from the Jules 
Gonin Eye Hospital, Lausanne, Switzerland. T o be 
included, patients had to present clear signs of 
AMD without potentially interfering retinopathy/ 
maculopathy (eg diabetic). They had to be at least 
50 years of age at the time the colour photographs 
were taken; slide or digital cameras were used 
(Zeiss FK30, Zeiss, Jena, Germany; Canon 60Z/ 
60U, Canon, Utsunomiyashi, Tochigiken, Japan; 
and T opcon TRC50IA or TRC50IX, T opcon, 
Capelle A/D Iyssel, the Netherlands). 
The study adhered to the tenets of the 
Declaration of Helsinki and was approved by the 
locally appointed ethics committee. All patients 
gave their informed consent. Initially, 466 unre-
la ted patients were enrolled, of which 41 were 
ultimately excluded: 24 for incomplete clinical 
data, 12 because the diagnosis of AMD was not 
confirmed and five for potentially confounding 
retinopathy. Therefore, genetic and statistical 
analysis was performed on 425 patients with 
AMD (EDTA blood samples were taken for DNA 
extraction). 
Study population: control selection 
A control population was selected only for 
confirmation of the AMD risk association with 
the described polymorphism, for the Swiss popula-
tion. Individuals serving as controls were unrelated 
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Table 1 Study population by allele frequency and genotypic groups 
Allele frequency Genotype frequency p Value 
Genotype 
AMD cases* 
Controls* 
Age of AMD cases (years)t 
Age of contrais (years)t 
*Values are means (%). 
tValues are means (SD). 
T c 
352 (41.9) 488 (58.1) 
65 (65) 35 (35) 
AMD, age-related macular degeneration. 
TT 
71 (16.9) 
19 (38) 
73.9 (8.8) 
73.5 (5.4) 
to the AMD patients, or were spouses. They had to be free of 
any signs of AMD and other retinopathies/maculopathies. 
Colour fondus photographs were taken. T o reduce the risk of 
including yet unrevealed AMD patients, only individuals older 
than 65 years were included. Informed consent was given by all 
contra! individuals. 
Sixty-three individuals agreed to participate. However, 11 
were excluded: seven due to signs of AMD and four who had 
missing or poor quality photographs (secondary to age-related 
cataract). Blood samples from the remaining 52 controls were 
analysed for CFH Y 402H polymorphism (EDT A blood samples 
were taken for DNA extraction). 
Fundus grading 
Colour fondus photographs were graded before genetic analysis 
was performed and the results were not communicated to the 
geneticist. Each eye was graded independently. The reading was 
clone by one of us (I Droz), based on the International 
Classification and Grading System for AMD.42 This classifica-
tion was chosen rather than the Age-Related Eye Disease Study 
(AREDS) severity scale43 44 or the clinical age-related maculo-
pathy staging (CARMS) system45 because our primary interest 
was the phenotype of AMD rather than progression of the 
disease in terms of stages. Because of the complexity of the 
International Classification and Grading System, we considered 
it necessary to reduce the number of parameters. Drusen criteria 
were maintained (largest size, predominant size, total surface, 
distribution), while the classification of pigmentary anomalies 
was changed toits presence/absence, with foveal or extrafoveal 
location; GA and CNV were classified as present or absent. The 
grid template was used as described in the International 
Classification.42 
In terms of AMD stages, we distinguished early/intermediate 
AMD (extrafoveal GA allowed) from late AMD, classified as 
central GA or CNV (any sign). As the neovascular form is 
considered more severe, it was regarded to be dominant over 
any co-existing GA. 
A study by Postel et al,46 comparing AMD phenotypes 
between singleton and multiplex families, found a significant 
difference between the two groups in terms of the presence of 
peripheral drusen. We therefore added this parameter of 
TC 
210 (50) 
27 (54) 
76.4 (7.6) 
75.7 (6.3) 
cc 
139 (33.1) 
4 (8) 
75.4 (7.4) 
73.8 (7.8) 
Total 
420 (100) 
50 (100) 
75.7 (7.8) 
74.9 (6.2) 
Allele Genotype 
1 x10-s 5x10- 5 
0.995 
peripheral drusen (presence/absence), i.e., those located outside 
of the temporal vascular arcades (>125 µm). 
Genotyping 
DNA was extracted from peripheral blood using the 
NucleonBacc2 and the protocol provided by the manufacturer 
(GE Healthcare Europe, Otelfingen, Switzerland). The single 
nucleotide polymorphism rs1061170, located in the complement 
factor H gene and responsible for the Y 402H variant, was 
evaluated after polymerase chain reaction (PCR) amplification 
and denaturing high-performance liquid chromatography 
(DHPLC) analysis. PCR was performed with primers forward 
(5'-TTCTTTTTGTGCAAACCTTTGTT-3') and reverse (5'-
CCATTGGTAAAACAAGGTGACAT-3'). Thirty-five cycles of 
PCR were performed (denaturation at 95°C for 1 min; anneal-
ing at 58°C for 1 min; extension at 72°C for 1 min). The PCR 
products were screened by DHPLC (55°C1 57.4% start B, 0.56 
time shift and a 1.5 ml/min flow rate). 
Statistical analysis 
Statistical analyses were clone by an epidemiological centre 
(Center for Clinical Epidemiology, University of Lausanne, 
S wi tzerland). 
Before analysing the genotype-phenotype association, we set 
out to replicate the association of CFH Y 402H polymorphism 
with AMD in our population: the relative risk for AMD was 
analysed for CC homozygotes, CT heterocygotes and for both 
groups together (presence of at least one risk C allele), correcting 
for age and sex (logistic regression), comparing patients and 
controls. 
Investigation of phenotypic features was performed in two 
steps: first, the relative risk for late AMD stages (GA and CNV) 
was analysed for CC homozygotes and CT heterocygotes, 
correcting for age and sex, using the more severely affected eye. 
The grading criteria for drusen and pigmentary changes were 
then analysed (chi-square test), using the less affected eye. The 
decision to use the less affected eye was made because grading 
data were often more complete in the absence of obscuring 
lesions such as GA or CNV. Concordance of drusen criteria 
between the two eyes was actually good, with kappa ranging 
between 0.52 and 0.78. 
Table 2 Stage of AMD by allele frequency and genotypic group 
Allele frequency Genotype frequency p Value* 
Genotype T c TT TC cc Total Alle le Genotype 
Early/intermediate AMD 135 (43) 177 (57) 26 (16.7) 83 (53.2) 47 (30.1) 156 (100) 
GA (central) 41 (37) 71 (63) 7 (12.5) 27 (48.2) 22 (39.3) 56 (100) 0.26 0.42 
CNV 176 (42) 240 (58) 38 (18.3) 100 (48.1) 70 (33.6) 208 (100) 0.86 0.63 
Values are n (%). 
*p Values comparing late AMD with early AMD (chi-square test). 
AMD, age-related macular degeneration; CNV, choroidal neovascularisation; GA, geographic atrophy. 
514 Br J Ophthalmol 2008;92:513-517. doi:10.1136/bjo.2007.127811 
• • 
• • 
' •. : . 
1 .,. 
Table 3 Relative risk ta develop late stages of age-related macular degeneration (AMD) versus early/ 
intermediate stages, according ta the potential risk genotypes compared with the TT homozygotes 
TC CC 
Late phenotype OR 95% Cl 
Geographic atrophy 1.005 0.37 ta 2.66 
Neovascular AMD 0.78 0.42 to 1.41 
Any late AMD 0.82 0.46 to 1.46 
Ali results are corrected for age and sex. 
RESULTS 
The average age of AMD patients and of controls was similar 
(75.7 and 74.9 years, respectively). Among the 425 AMD 
patients, there were 278 women (65.4%); in the contra! group, 
there were 26 women (50%). Genetie results were successfolly 
obtained for all individuals, except for five AMD patients and 
two contrais. Statistical analysis was thus performed on 420 
AMD cases and 50 contrais. 
The three possible genotypes (TT, TC and CC) of the CFH 
Y 402H polymorphism showed the following distribution: of the 
420 AMD cases included, 71 (16.9%) had TT, 210 (50%) had TC 
and 139 (33.1%) had CC (table 1). Of the 50 contrai subjects, 19 
(38%) had TT, 27 (54%) had CT and four (8%) had the CC 
genotype (table 1). 
After correcting for age and sex in a logistic regression 
analysis, the C allele showed a significant association with 
AMD in this Swiss population, with an OR of 9.05 (95% CI 2.92 
to 27.98; p<0.0001) for CC homozygotes and an OR of 2.00 
(95% CI 1.02 to 3.94; p = 0.04) for TC heterozygotes compared 
with TT homozygotes. The OR for the presence of at least one 
C allele (TC or CC) was 2.95 (95% CI 1.54 to 5.67; p = 0.001), 
with an estimated population attributable risk (PAR) of 55%. 
Table 2 shows the distribution of AMD patients according to 
their disease stage and genotype. 
The analysis for the relative risk to develop GA or CNV, 
according to a given genotype, showed no statistically 
significant difference for TC heterocygotes and CC homozy-
gotes compared with TT homozygotes (table 3). 
Analysis of drusen criteria and pigmentary changes showed 
the following results (table 4). 
No significant difference was found between genetic groups 
with respect to drusen size (largest and predominant), drusen 
covered surface, drusen distribution and pigmentary changes. 
However, peripheral drusen did show a significant association 
with genotype, being more common in individuals with the risk 
allele C, particularly if homozygous (p = 0.028). 
Regrouping of all individuals with circular drusen distribution 
(relative sparing of the central 500 µm), and comparison with 
those with central drusen predominance showed a significant 
trend for central drusen location in patients with the risk allele, 
particularly if homozygous (p = 0.049). Both factors combined 
remained significantly associated with the risk allele (p = 0.030). 
DISCUSSION 
The CFH Y402H polymorphism (rs1061170) is an important 
genetic AMD risk factor in the white American population,20-28 
and this was later confirmed in French,47 UK,37 Icelandic,27 
Italian38 and Russian48 populations. It should be mentioned, 
however, that the strongest CFH association was found for a 
different non-coding variant (rs1410996)26 30, the only variant 
that has also been shown significant in the Japanese popula-
tion.49-52 In the Chinese population results were inconsistent.53 54 
The first part of our study confirmed the risk association with 
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p Value OR 95% Cl p Value 
0.99 1.52 0.55 to 4.15 0.41 
0.41 0.996 0.53 to 1.88 0.99 
0.51 1.07 0.58 to 1.97 0.83 
AMD in the Swiss population; the OR was within the reported 
range (at least one C allele: between 2.4523 and 4.36;28 C 
homozygous: between 3.3323 and 8.35.24) Correspondingly, our 
calculation of the PAR (55%) is similar to the result of a meta-
analysis of the first eight reports (PAR 58.9%).55 This confirma-
tion in our population was important before focusing on the 
analysis of the genotype-phenotype association within the 
AMD group. Given the agreement with the literature, we 
considered the relatively small number of controls sufficient for 
confirming the reported genetic risk association in our popula-
tion. 
Severa! studies have investigated the influence of CFH Y 402H 
polymorphism on the AMD phenotype in terms of GA or CNV, 
as a poorly regulated complement cascade due to the CFH 
polymorphism could well enhance cellular damage, leading 
ultimately to atrophy or neovascular response. 41 56 57 In our 
study, we were not able to confirm any significant difference in 
the prevalence of either GA or CNV, or early/intermediate 
AMD, in relation to the Y 402H genotype. These results fit well 
into the inconsistent results reported to date: some investigators 
have suggested a higher risk for neovascular AMD,22 23 35 36 while 
others found a trend towards atrophie AMD,20 28 31 33 34 58 or 
found like us no difference at all.27 30 37 38 It may well be that the 
influence of Y 402H polymorphism on the type of la te AMD is 
min or. 
However, there is good evidence for increased risk for 
progression associated with the CFH polymorphism from two 
studies with longitudinal date.59 60 Similarly, Despriet and 
colleagues found a progressively increasing relative risk for each 
successive stage of AMD. 20 In our study, however, we did not 
find higher rates of Iate AMD associated with the CFH Y402H 
genotype. 
" In the literature, unspecified genetic influence was shown on 
early phenotype criteria of AMD, in terms of drusen and 
pigmentary changes. 15 17 19 Our investigation on the specific 
influence of the CFH polymorphism showed a significant 
association with the presence of drusen outside the vascular 
arcades and a significant trend for foveal drusen location (as 
well as the combination of both criteria). These findings might 
reflect a wider spread distribution of drusen in the CFH risk 
situation. 
Previous reports described extramacular and peripheral drusen 
in hereditary patterns within families whose older members 
have advanced AMD, 61 and more common in cases occurring in 
multiplex families than in patients from singleton families. 46 
However, the only study to look at the relation of drusen 
characteristics with the genotypes of CFH and LOC387715, 
found no significant association with peripheral drusen, as well 
as with all other early phenotypical features of AMD.34 
In our study, all other drusen characteristics (largest drusen, 
predominant drusen, surface covered by drusen, location nasal 
to the dise) were similarly not associated with the investigated 
CFH polymorphism. In a sense this is not surprising, as, for a 
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Table 4 Proportion of individuals with a specific phenotypic feature by genotypic group 
p Value 
TT TC cc Alle le Genotype 
Drusen size (µm) 0.19 0.19 
<63 0.050 0.027 0.024 
63-125 0.367 0.225 0.244 
125-250 0.367 0.438 0.366 
>250 0.217 0.310 0.366 
Predominant drusen (µm) 0.97 0.33 
<63 0.161 0.096 0.122 
63-125 0.419 0.394 0.431 
125-250 0.274 0.415 0.317 
>250 0.145 0.096 0.130 
Surface covered by drusen (%) 0.12 0.32 
<10 0.540 0.465 0.362 
10-25 0.220 0.245 0.362 
25-50 0.180 0.214 0.210 
>50 0.060 0.076 0.067 
Main drusen localisation 0.12 0.33 
Central circle 0.480 0.618 0.687 
lntermediate circle 0.300 0.204 0.192 0.025* 0.049* 
Outer circle 0.160 0.132 0.101 
Outside the circles 0.060 0.046 0.020 
Peripheral drusen 0.012 0.028 
Pre sent 0.300 0.407 0.493 
Absent 0.700 0.593 0.507 
Peripheral drusen and central drusen location 0.017 0.030 
Combined 0.086 0.196 0.239 
None or not combined 0.914 0.804 0.761 
Pigment changes 0.64 0.74 
Absent 0.482 0.469 0.444 
Extrafoveal 0.107 0.179 0.176 
Foveal 0.411 0.352 0.380 
p Value calculation with chi-square test for the genotype frequency and the allele frequency (data serving for the calculation of the 
latter not shown). 
*p Value for central circle versus intermediate circle, outer circle and ouside the circle (CC genotype). 
complex genetic disorder such as AMD, other genes may be 
responsible for early phenotypes of the disease. On the other hand, 
several observations suggest a role of CFH on drusen phenotype. 
First, it was shown that CFH polymorphism increases the risk 
even for early stages of AMD.20 27 Second, drusen were hypothe-
sised to be the result of inflammatory and/or immune-mediated 
processes,62 with accumulation of CFH and various factors of the 
complement pathway.22 40 41 Third, particularly cuticular drusen 
are strongly associated with CFH polymorphism39 and they are 
also a typical feature in membranoproliferative glomerulonephritis 
(MPGN) type II, a disorder in which CFH is implicated. And 
fourth, the low prevalence and nearly absent impact of the CFH 
Y 402H polymorphism in Asians49~51 53 54 coincides with the Asian 
phenotype of AMD, that is not usually characterised by drusen in 
its early stages.63 64 
We acknowledge that a greater number of patients may be 
needed to detect the phenotypical influence of genetic 
polymorphisms. Grading variables of the drusen phenotype 
may change over time as the disease progresses, thereby 
confounding phenotype and stage of the disease. 
Furthermore, we acknowledge that in our study the absence 
of data about the smoking status (environmental risk factor for 
disease susceptibility) precluded statistical correction. However, 
previous reports found no association with the AMD type, 65 
except for neovascular AMD. 66 
Future research about the genotype-phenotype association in 
AMD will have to deal with multiple challenges: 
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~ The potential influence of numerous genes and environ-
mental factors on the phenotype. Careful history-taking, 
general examination, screening of all known genetic risk 
factors and a prospective study design are needed. 
~ Different stages of the disease may be confounding; long-
itudinal data may be needed to address this problem. 
~ Additional aspects of phenotype could include visual 
fonction and age at onset of the AMD. The role of these 
variables has not yet been established. 
Further advances in research about the genotype-phenotype 
correlation in AMD may prove valuable to better understand of 
the genetic influence on the pathogenesis of AMD, to develop new 
prophylactic and therapeutic measures, and ultimately to care for 
patients in an individualised, and thereby cost-effective way. 
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